Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei.
Macrophage migration inhibitory factor (MIF) is an essential regulator of the macrophage responses to endotoxin. MIF also has the ability to override the anti-inflammatory actions of glucocorticoids during an immune response, and is thus an important pro-inflammatory factor. The presence of MIF in cells of the anterior pituitary has been described, and high levels of MIF in other rapidly proliferating tIssues have also been demonstrated. It has been hypothesised that MIF release from these cells is influenced by the hypothalamo-pituitary-adrenal axis, and that ACTH and MIF are released simultaneously to exert counter-regulatory effects on cortisol. However, another intracellular role for MIF has also been suggested as it has been shown that MIF exerts an effect on the inhibitory cell cycle control protein p27 through an interaction with Jab1, a protein implicated in p27 degradation. We studied MIF expression in different normal and adenomatous human pituitary samples using immunohistochemistry and RT-PCR. There was evidence of co-immunoprecipitation of MIF with Jab1, suggesting an interaction of the two proteins. Our results showed that there is increased expression of MIF protein in the nuclei of all pituitary adenomas compared with normal tIssue (P=0.0067), but there was no statistically significant difference in nuclear MIF expression between the different adenoma types. Nuclear MIF expression correlated positively with p27 and its phosphorylated form in normal tIssue (P=0.0028 and P<0.0001); however, this relationship was not seen in the adenoma samples. Cytoplasmic expression of MIF was found to be variable both in normal and adenomatous samples, with no consistent pattern. MIF mRNA was demonstrated to be present in all tumour and normal samples studied. Somatotroph tumours showed higher MIF mRNA expression compared with normal pituitary or other types of adenomas. In conclusion, MIF is expressed in cell nuclei in pituitary adenomas to a greater extent than in normal pituitary tIssue. We speculate that it may play a role in the control of the cell cycle, but whether its higher level in adenomas is a cause or a consequence of the tumorigenic process remains to be clarified.
Pyle
M E
ME
Endocrine Oncology, Department of Endocrinology, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK.
Korbonits
M
M
Gueorguiev
M
M
Jordan
S
S
Kola
B
B
Morris
D G
DG
Meinhardt
A
A
Powell
M P
MP
Claret
F X
FX
Zhang
Q
Q
Metz
C
C
Bucala
R
R
Grossman
A B
AB
D000236:Adenoma / Q000737:chemistry*; D000328:Adult; D000368:Aged; D002467:Cell Nucleus; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008263:Macrophage Migration-Inhibitory Factors / Q000032:analysis* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000737:chemistry*; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured
D008263:Macrophage Migration-Inhibitory Factors; D012333:RNA, Messenger